Please wait while we open this resource.
K
Clinical reviews
LDL CHOLESTEROL LOWERING WITH EVOLOCUMAB BEFORE PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE MYOCARDIAL INFARCTION
AMUNDSEN Investigators of the ACTION Study Group
PDF20269 pages554 KB
The AMUNDSEN Randomized Clinical Trial evaluates the efficacy of evolocumab in lowering LDL cholesterol before percutaneous coronary intervention in patients with acute myocardial infarction. The trial highlights the importance of achieving optimal LDL cholesterol levels to improve clinical outcomes in this high-risk population. Results indicate that a significant proportion of patients achieved LDL cholesterol levels below recommended thresholds, suggesting the potential for enhanced lipid management strategies in acute care settings.
Sign in to open
Ask this resource
Answers use this document only.
Your first question is free.
More like this
Resources from the same specialty and type. Curated links will replace these when added.
Clinical Resources
Documents that extend or complement this resource.
SURVIVAL AFTER INITIAL STRESS TESTING VS ANATOMIC TESTING IN SUSPECTED CORONARY ARTERY DISEASE
Same clinical topic · Cardiology
PRACTICAL CARDIO-ONCOLOGY
Same clinical topic · Cardiology
OXFORD CARDIOLOGY LIBRARY: Hypertension
Same clinical topic · Cardiology
CARDIAC INVOLVEMENT IN PARASITIC INFECTIONS
Same clinical topic · Cardiology
The Athlete’s ECG
Same clinical topic · Cardiology
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review
Same clinical topic · Cardiology
Current ECG Aspects of Interatrial Block
Same clinical topic · Cardiology
Arrhythmic mitral valve prolapse in 2023: Evidence-based update
Same clinical topic · Cardiology
INTERPRETING THE NORMAL PACEMAKER
Same clinical topic · Cardiology